Show simple item record

dc.contributor.authorGlass, B
dc.contributor.authorMangan, M
dc.contributor.authorHaywood, A
dc.contributor.editorA. Li Wan Po and M.J. Kendall
dc.date.accessioned2017-05-03T14:23:14Z
dc.date.available2017-05-03T14:23:14Z
dc.date.issued2009
dc.date.modified2010-08-16T06:48:04Z
dc.identifier.issn0269-4727
dc.identifier.doi10.1111/j.1365-2710.2008.00981.x
dc.identifier.urihttp://hdl.handle.net/10072/22384
dc.description.abstractBackground and objective: Patients are increasingly requiring their medications to be repackaged into dose administration aids because of the positive outcomes associated with reduction in medication related hospitalization and adverse effects due to improved medicines management. Since the stability of these repackaged medications is not the responsibility of manufacturer, it is important that drug substances with potential stability issues be identified. Thus the objective of this study was to evaluate the stability of prochlorperazine, a light sensitive drug repackaged into dose administration aids (DAAs), in order to provide guidelines to the pharmacist and advice to the patient on appropriate storage. Methods: Prochlorperazine tablets were stored repackaged in DAAs and in their original packaging for 8 weeks at ambient (25 ᠱ û 60 ᠱ絥 RH), accelerated (40 ᠱ û 75 ᠱ絥 RH) and in-use conditions encountered in situ both in a pharmacy and the patients' home. They were assessed for both chemical (using a validated HPLC method) and physical stability according to British Pharmacopoeial (BP) standards. In addition, photostability testing was undertaken under ICH conditions. Results and discussion: Chemical and physical stability was confirmed to be within BP Limits. There were, however, noticeable organoleptic changes in the tablets stored under in-use conditions with a progressive grey discolouration over the 8 weeks, starting in week 2. Conclusion: Despite the confirmation of physical and chemical stability within BP limits, the discoloration and the potential for photodegradants to cause adverse effects in patients must lead us to draw the conclusion that the quality of this medication has been compromised. Pharmacists thus need to take this into account in repackaging and storage of prochlorperazine in DAAs and advise patients to store their DAA protected from light, heat and humidity.
dc.description.peerreviewedYes
dc.description.publicationstatusYes
dc.languageEnglish
dc.language.isoeng
dc.publisherBlackwell Publishing Ltd
dc.publisher.placeUnited Kingdom
dc.relation.ispartofstudentpublicationN
dc.relation.ispartofpagefrom161
dc.relation.ispartofpageto169
dc.relation.ispartofjournalJournal of Clinical Pharmacy and Therapeutics
dc.relation.ispartofvolume34
dc.rights.retentionY
dc.subject.fieldofresearchPharmacology and pharmaceutical sciences
dc.subject.fieldofresearchcode3214
dc.titleProchlorperazine tablets repackaged into dose administration aids: can the patient be assured of quality?
dc.typeJournal article
dc.type.descriptionC1 - Articles
dc.type.codeC - Journal Articles
gro.date.issued2009
gro.hasfulltextNo Full Text
gro.griffith.authorHaywood, Alison


Files in this item

FilesSizeFormatView

There are no files associated with this item.

This item appears in the following Collection(s)

  • Journal articles
    Contains articles published by Griffith authors in scholarly journals.

Show simple item record